Keep Updated

Washington Summary May 2018

Tolvaptan (brand name JYNARQUE™) In April 2018, the FDA approved the first drug available in the US to treat ADPKD. Tolvaptan is a selective vasopressin V2-receptor antagonist. This means it blocks vasopressin, an anti-diuretic hormone secreted by the pituitary gland, […]

PKD Foundation |

Washington Summary April 2018

PKDF Priorities PKD Foundation is submitting its FY19 funding requests to the House and Senate Appropriations Committees. PKDF is asking Congress to return PKD to the list of eligible research programs under the Department of Defense’s Congressionally Directed Medical Research […]

PKD Foundation |

Washington Summary March 2018

Advocacy Alert Last week, the PKD Foundation asked its advocates to urge Congress to keep PKD on the list of eligible research programs for Fiscal Year 2018 under the Department of Defense’s Congressionally Directed Medical Research Program (CDMRP). Thank you […]

PKD Foundation |

Washington Summary February 2018

Health Research and Other Spending Programs On Feb. 9, Congress approved the Bipartisan Budget Act of 2018 that kept government departments and agencies (such as NIH) open until March 23. The short-term funding bill is part of a larger budget […]

PKD Foundation |

Washington Summary January 2018

Second Session of Congress Begins Congress has returned for what could be a busy 2018. The agenda includes the children’s health program (CHIP) and a number of non-health-related national issues: raising the debt ceiling so the US can pay its […]

PKD Foundation |

Washington Summary December 2017

Tax Reform and Health Care The details of the final tax bill (HR 1) were released on Dec. 15. Here are the provisions impacting health-related issues. Deduction of medical expenses: The final bill states that for two years (2017 and […]

PKD Foundation |

Washington Summary November 2017

Health Care Congress continues to discuss ways to stabilize the ACA individual insurance market. More than 200 groups have endorsed the proposal drafted by Sens. Lamar Alexander (R-TN) and Patty Murray (D-WA). Other Senators and Representatives have their own proposals […]

PKD Foundation |

Washington Summary October 2017

Health Care On Sept. 26, Senate Majority Leader Mitch McConnell (R-KY) indicated that the Senate would not vote on the most recent attempt to amend the Affordable Care Act (ACA).  Sens. Lamar Alexander (R-TN) and Patty Murray (D-WA) may seek […]

PKD Foundation |

Tolvaptan and lixivaptan: what’s the difference?

In response to the news about lixivaptan’s orphan drug designation, there have been questions from the PKD community about the difference between the investigational drug and another potential ADPKD treatment, tolvaptan. Tolvaptan and lixivaptan are vasopressin V2 receptor antagonists, meaning […]

PKD Foundation |

Lixivaptan granted orphan drug status for ADPKD

An investigational drug being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD) has received orphan drug designation by the U.S. Food and Drug Administration (FDA). Lixivaptan is a potent, selective vasopressin V2 receptor antagonist which may delay […]

PKD Foundation |